[바이오대박속보뉴스]상한가인 뉴델리발 뉴스가 떴어!!
이 뉴스를 시장은 무시하지마!!!!
이 뉴스가 쩜상 잠재적 뉴스야!!!

Zydus Cadilas Covid vaccine will be rolled out soon: V K Paul

By Press Trust of India | New Delhi | Last Updated at October 17 2021 17:51 IST


The government will take a final decision on vaccinating children and adolescents against coronavirus on the basis of overall scientific rationale as well as the supply situation of vaccines available for those below 18 years old, COVID Task Force chief V K Paul said on Sunday.

Paul, who has been playing a key role in the governments efforts in the fight against the coronavirus pandemic, also cautioned that even though infections are coming down and the second wave is subsiding, it will not be fair now to say that the worst is over since many countries have seen more than two waves.

Currently, three vaccines -- Covishield, Covaxin and Sputnik V -- being administered in the country are only for those above 18 years of age. All of them are two-dose vaccines.


 Cadilas indigenously developed needle-free COVID-19 vaccine ZyCoV-D is set to become the first vaccine that will be available in India for those in the age group of 12-18 years. It has received Emergency Use Authorisation (EUA).

"We do know that several countries have introduced vaccination for adolescents (people) and children. We will take a final decision based on the overall scientific rationale and the supply situation of the child licenced vaccines, going forward," Paul told PTI in an interview.

An expert panel of Indias central drug authority has recommended granting EUA to Bharat Biotechs Covaxin for children and adolescents in the 2-18 years age group with certain conditions.

If approved by the Drugs Controller General of India (DCGI), it will be the second vaccine after ZyCoV-D to get EUA for use among those below 18 years.

The National Technical Advisory Group on Immunisation (NTAGI) is looking at how ZyCov-D should be positioned for most optimum use.

According to Paul, Covaxin is a part of the adult vaccination programme and how to provision the vaccine, if at all for children, has to be also examined in the totality of the requirements of the vaccination programme.

"A pragmatic decision (on vaccination of children and adolescents) can be taken (only) by balancing the supply and the potential eligibility," he said.

While noting it will not be possible now to give a particular timeline on when COVID vaccination will start for children, Paul said, "The preparation for incorporation of Zydus Cadilas vaccine into the vaccination programme is proceeding well, training is already being held. NTAGI advice for the best use of the vaccine is explored. So soon, this will be rolled out".

According to Paul, children are part and parcel of the chains of COVID transmission and are infected in large numbers. At the same time, COVID infections in children are very mild or asymptomatic, and that is one side of the story.

On the other side, he said that once there is enough vaccine available that can be used in children, "so why not protect them".

Schools have reopened in many states, mainly for higher classes.

When asked whether the worst of the pandemic is over, Paul said, "It is reassuring that the number of COVID cases are now on the decline and the second wave is now subsiding but to say that the worst is over will not be fair because we have seen in other nations, there have been more than two waves".

Cautioning that the country is passing through a phase when there are festivals and potential gatherings, he said this is a critical phase as the virus can spread again.

"We have seen that even in other countries where vaccine coverage is good, the escalation in the pandemic can happen and has happened.

"Therefore, certainly we should not assume that this situation of the declining trend will continue and definitely we should not think that the worst is over, we have to be ever watchful," he emphasised.

While stressing that the vaccination programme has picked up huge speed, Paul also said that states which are for whatever reasons lagging behind must work hard and must push vaccination.

"Now, of course, there is no dearth, no inadequacy of vaccine supply. They are as of today 10 crore doses of vaccines with the state governments for the vaccination programme," he said.

As the supply situation is excellent, Paul said the states must ensure that they reach out to those who are left out in the vaccination programme.

"Given the present generous vaccine supply situation and the performance of the vaccine implementation programme, it is well within our grasp to accomplish universal vaccination of the adult population," he asserted.

On some reports that India simply will not have enough syringes for COVID vaccines if every single adult is to be fully vaccinated by the end of the year, Paul said, "there is no problem of syringe availability, we are in a good shape".

The country recorded 14,146 fresh COVID infections in a day while active cases declined to 1,95,846, the lowest in 220 days, according to the Union Health Ministrys data released on Sunday
ㅡㅡㅡㅡ
시장에서 이 빅뉴스에 대한 국내 언론 뉴스는 지금도 없다
완전 대박뉴스를 여기 종토방에서 제일 먼저 접한다

최근 뉴스대로 곧 출시한다는 것은 백신제조사와 인도정부간의 백신가격을 이미 정했다는 것이고

그 가격으로 엔지켐생명과학과 자이더스 카딜라 간의 본계약은 이미 체결 아니면 막바지 조율과 사인만

아마도 백신가격 미결정으로 엔지켐생명과학은 한 차례
1달 안에 재공시한다고 공시로 추측

지난번 엔지켐 공시대로 구체적으로 협의 중이라고 발표

1조5천만 도즈
1도즈에 만원
1조5천억

엔지켐생명과학 그동안 적자를 한방에 복구
유증실시에 앞어서 KB금융에서 먼저 1500억을 수령
그 자금으로 빠르면 올해 안에 백신을 제조할 수도

엔지켐생명과학 최대 케파는 5억도즈까지에 5조원대 매출

pDNA 장점은
no 주사기 no 고통 no 피로도
순간적으로 피부에 주사
12세 청소년부터 접종가능
인도 임상3상 완료

자이더스 카디날은
WHO에 가난한 나라를 위해 긴급사용승인 이미 신청
허가 떨어지면 엔지켐생명과학은 향후 확실한 매출을
글로벌로 보장 받는 셈

화이자 모더나는 부자나라들만의 백신이라 비난 받고
그들 국가들이 기축통화위치에서 대량 구입후
노마스크 규제를 먼저 풀었다.

인도는 세계 백신을 제조하는 최대 공장 허브

대단히 굿잡 알았쩨!!!!